These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 33607383)

  • 21. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.
    Ornstein MC; Calabrese C; Wood LS; Kirchner E; Profusek P; Allman KD; Martin A; Kontzias A; Grivas P; Garcia JA; Calabrese LH; Rini BI
    Clin Genitourin Cancer; 2019 Jun; 17(3):177-182. PubMed ID: 30824360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma.
    Singh V; Chu Y; Gupta V; Zhao CW
    Cureus; 2020 Jun; 12(6):e8395. PubMed ID: 32637277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM
    Curti B; Daniels GA; McDermott DF; Clark JI; Kaufman HL; Logan TF; Singh J; Kaur M; Luna TL; Gregory N; Morse MA; Wong MKK; Dutcher JP
    J Immunother Cancer; 2017 Dec; 5(1):102. PubMed ID: 29254506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity.
    Sorah JD; Rose TL; Radhakrishna R; Derebail VK; Milowsky MI
    J Immunother; 2021 Apr; 44(3):127-131. PubMed ID: 32925564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing their ability to cause acute kidney injury and informing their proper use.
    Min JW; Lim JU
    Semin Oncol; 2022 Apr; 49(2):141-147. PubMed ID: 35264308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis.
    Kanbay M; Yildiz AB; Siriopol D; Vehbi S; Hasbal NB; Kesgin YE; Celayir M; Selcukbiricik F; Covic A; Perazella MA
    Int Urol Nephrol; 2023 Apr; 55(4):1025-1032. PubMed ID: 36282399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
    Perazella MA; Shirali AC
    Kidney Int; 2020 Jan; 97(1):62-74. PubMed ID: 31685311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute kidney injury in patients treated with immune checkpoint inhibitors.
    Gupta S; Short SAP; Sise ME; Prosek JM; Madhavan SM; Soler MJ; Ostermann M; Herrmann SM; Abudayyeh A; Anand S; Glezerman I; Motwani SS; Murakami N; Wanchoo R; Ortiz-Melo DI; Rashidi A; Sprangers B; Aggarwal V; Malik AB; Loew S; Carlos CA; Chang WT; Beckerman P; Mithani Z; Shah CV; Renaghan AD; Seigneux S; Campedel L; Kitchlu A; Shin DS; Rangarajan S; Deshpande P; Coppock G; Eijgelsheim M; Seethapathy H; Lee MD; Strohbehn IA; Owen DH; Husain M; Garcia-Carro C; Bermejo S; Lumlertgul N; Seylanova N; Flanders L; Isik B; Mamlouk O; Lin JS; Garcia P; Kaghazchi A; Khanin Y; Kansal SK; Wauters E; Chandra S; Schmidt-Ott KM; Hsu RK; Tio MC; Sarvode Mothi S; Singh H; Schrag D; Jhaveri KD; Reynolds KL; Cortazar FB; Leaf DE;
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study.
    Jamieson L; Forster MD; Zaki K; Mithra S; Alli H; O'Connor A; Patel A; Wong ICK; Chambers P
    BMC Cancer; 2020 Aug; 20(1):743. PubMed ID: 32778064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
    Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
    BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study.
    Zhou P; Liu B; Shen N; Fan X; Lu S; Kong Z; Gao Y; Lv Z; Wang R
    Ren Fail; 2024 Dec; 46(1):2326186. PubMed ID: 38466161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort.
    Stein C; Burtey S; Mancini J; Pelletier M; Sallée M; Brunet P; Berbis P; Grob JJ; Honoré S; Gaudy C; Jourde-Chiche N
    Nephrol Dial Transplant; 2021 Aug; 36(9):1664-1674. PubMed ID: 32941608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colistimethate sodium and acute kidney injury: Incidence, risk factors, outcome and prognosis of renal function.
    Pampa-Saico S; Pintado V; Muriel A; Caravaca-Fontan F; Yerovi-León E; Rojo-Sanchis A; Del Rey JM; Teresa Tenorio M; Liaño F
    Nefrologia (Engl Ed); 2020; 40(6):647-654. PubMed ID: 32473742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.
    Teuma C; Perier-Muzet M; Pelletier S; Nouvier M; Amini-Adl M; Dijoud F; Duru G; Thomas L; Fouque D; Laville M; Dalle S
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):419-26. PubMed ID: 27371224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.
    Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
    Kidney Int; 2017 Jun; 91(6):1482-1494. PubMed ID: 28237709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study.
    Liu K; Qin Z; Ge Y; Bian A; Xu X; Wu B; Xing C; Mao H
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5061-5070. PubMed ID: 36326913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint inhibitors and acute kidney injury.
    Zhou P; Gao Y; Kong Z; Wang J; Si S; Han W; Li J; Lv Z; Wang R
    Front Immunol; 2024; 15():1353339. PubMed ID: 38464524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience.
    Oleas D; Bolufer M; Agraz I; Felip E; Muñoz E; Gabaldón A; Bury R; Espinel E; Serón D; García-Carro C; Soler MJ
    Clin Kidney J; 2021 May; 14(5):1364-1370. PubMed ID: 34221369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk Factors Analysis of AKI in Patients with Primary Non-small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitor.
    Ying JM; Yan F
    Iran J Kidney Dis; 2024 Mar; 18(2):108-117. PubMed ID: 38660695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.